Compounds > levodopa

Page last updated: 2024-08-17

levodopa and cytarabine

levodopa has been researched along with cytarabine in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (25.00)	18.7374
1990's	1 (12.50)	18.2507
2000's	2 (25.00)	29.6817
2010's	3 (37.50)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Kent, S	1
Luque, FA; Petruska, P; Selhorst, JB	1
Kulkantrakorn, K; Petruska, PJ; Selhorst, JB	1
Bojko, A; Chutorian, AM; Edelberg, D; Frucht, S; Heier, L; Nygaard, T	1

Other Studies

8 other study(ies) available for levodopa and cytarabine

Article	Year
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21 Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship	2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6 Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics	2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Continuous drug delivery methods reflect progress in therapy for chronic diseases. Geriatrics, 1977, Volume: 32, Issue:9 Topics: Aged; Chronic Disease; Cytarabine; Dosage Forms; Drug Implants; Glaucoma; Humans; Injections, Intravenous; Leukemia; Levodopa; Neoplasms; Parkinson Disease; Pilocarpine; Research	1977
Parkinsonism induced by high-dose cytosine arabinoside. Movement disorders : official journal of the Movement Disorder Society, 1987, Volume: 2, Issue:3 Topics: Carbidopa; Cytarabine; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Leukemia, Myelomonocytic, Acute; Levodopa; Middle Aged; Parkinson Disease, Secondary	1987
Cytosine arabinoside and amphotericin B-induced parkinsonism. Annals of neurology, 1996, Volume: 39, Issue:3 Topics: Amphotericin B; Carbidopa; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myelomonocytic, Acute; Levodopa; Lung Diseases; Middle Aged; Parkinson Disease, Secondary	1996
Toxic pediatric parkinsonism: report of a child with metabolic studies and response to treatment. Journal of child neurology, 2003, Volume: 18, Issue:11 Topics: Antimetabolites, Antineoplastic; Antiparkinson Agents; Carbidopa; Child; Cytarabine; Humans; Levodopa; Male; Parkinson Disease, Secondary	2003